Lineage Cell Therapeutics, Inc.
HealthcareAMEX:LCTX · New York Stock Exchange American
-$0.01 today
Vol 1.00M · Avg 1.18M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$14.8M of revenue converted into -$64.2M of net income for the selected period. Gross margin is 96.6% and net margin is -544.2%, showing how much revenue survives after costs and taxes. EPS is $-0.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M +53.2% | $9.5M +6.2% | $8.9M -39.2% | $14.7M +277.4% | $3.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $845.0K +153.0% | $334.0K -50.2% | $671.0K -7.8% | $728.0K -48.9% | $1.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.7M +49.6% | $9.2M +10.8% | $8.3M -40.8% | $14.0M +465.8% | $2.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.2% -2.3pp | 96.5% +4.0pp | 92.5% -2.6pp | 95.0% +31.7pp | 63.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $17.7M +42.2% | $12.5M -20.6% | $15.7M +12.3% | $14.0M -58.8% | $33.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $18.5M +1.6% | $18.2M +5.0% | $17.3M -23.1% | $22.5M +23.6% | $18.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $35.5M +15.8% | $30.6M -7.2% | $33.0M -9.6% | $36.5M -29.4% | $51.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $699.0K +14.8% | $609.0K -12.0% | $692.0K -4.8% | $727.0K -16.7% | $873.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$67.9M -278.1% | -$18.0M +20.4% | -$22.6M +9.9% | -$25.1M +40.8% | -$42.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -466.8% -277.6pp | -189.2% +63.3pp | -252.5% -81.9pp | -170.6% +917.6pp | -1088.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$21.8M -1.4% | -$21.5M +13.2% | -$24.7M -9.8% | -$22.5M +54.2% | -$49.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -149.6% +76.5pp | -226.1% +50.4pp | -276.5% -123.3pp | -153.2% +1109.9pp | -1263.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.7M -1.4% | $1.7M +5.3% | $1.6M +96.5% | $829.0K +41350.0% | $2.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$46.9M -1718.4% | $2.9M +99.6% | $1.5M +144.1% | -$3.3M -155.4% | $5.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$68.6M -269.4% | -$18.6M +20.2% | -$23.3M +9.8% | -$25.8M +40.3% | -$43.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -471.6% -276.0pp | -195.6% +64.7pp | -260.3% -84.7pp | -175.6% +935.1pp | -1110.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$5.1M | $0 +100.0% | -$1.8M -433.3% | $541.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$63.5M -241.4% | -$18.6M +13.4% | -$21.5M +18.2% | -$26.3M +38.9% | -$43.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -436.5% -240.6pp | -195.9% +44.3pp | -240.2% -61.5pp | -178.7% +925.5pp | -1104.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -201.1% | -$0 +22.5% | -$0 +20.0% | -$0 +42.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -201.1% | -$0 +22.5% | -$0 +20.0% | -$0 +42.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $230.1M +14.9% | $200.2M +15.9% | $172.7M +1.7% | $169.8M +3.2% | $164.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $230.1M +14.9% | $200.2M +15.9% | $172.7M +1.7% | $169.8M +3.2% | $164.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$632.20M
Neurogene Inc.
NASDAQ:NGNE
$459.84M
PureTech Health plc
NASDAQ:PRTC
$424.07M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LCTX generate?
Lineage Cell Therapeutics, Inc. (LCTX) reported $14.56M of revenue in fiscal 2025.
Is LCTX profitable?
Lineage Cell Therapeutics, Inc. (LCTX) reported -$63,533,000.00 of net income, with a net margin of -436.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.